Progress in neoadjuvant and transformation therapy of pancreatic cancer
10.3760/cma.j.issn.0529-5815.2017.01.018
- VernacularTitle: 胰腺癌新辅助治疗和转化治疗的研究进展
- Author:
Dandan HU
1
;
Menghua DAI
Author Information
1. Depatment of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical Colloge, Beijing 100730, China
- Publication Type:Review
- Keywords:
Pancreatic neoplasms;
Drug therapy, combination;
Neoadjuvant therapy;
Transformation therapy
- From:
Chinese Journal of Surgery
2017;55(1):69-72
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic adenocarcinoma is a malignant disease with considerable metastatic potential.While surgical resection can be potentially curative, tumor recurrence remains an important cause of treatment failure.Neoadjuvant chemotherapy can increase rate of resectability by decreasing tumor burden and decrease recurrence rate by clearing microscopic disease in lymph nodes and vessels.Currently, neoadjuvant therapy is recommended for patients with resectable who has signs of high risks or borderline resectable pancreatic adenocarcinoma.However, no consensus exists in current literature on the evaluation of treatment response or operative timing.FOLFIRINOX has recently emerged as an effective chemotherapy regimen in several large clinical trials.
